Behavioral : Characterization
BehavioralBehavioral scales and neuropsychological tests; MRI, SPECT/PET
NCT Number: NCT04014673
The purpose of this study is to investigate whether cognitive deficits, structural and functional changes can be detected before symptom onset in presymptomatic progranuline mutation carriers. The main objectives of the project are to identify novel cognitive, brain imaging markers and peripheral biomarkers for early diagnosis of FTLD, and to follow disease progression.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Groupe Hospitalier Pitié-Salpêtrière - Charles Foix, Paris, France
The project focuses on the progranulin (PGRN) gene mutation, one of the most frequent genetic forms of frontotemporal dementias (FTD, or frontotemporal lobar degeneration, FTLD). FTD is the second commonest cause of degenerative dementia in presenium after Alzheimer's disease. Behavioral and cognitive impairments progressively lead to dementia. Two major pathological subtypes are now defined in FTD, FTD-TDP and FTD-TAU.
FTD is difficult to detect at an early stage, and no clinical, biological or imaging features can predict the underlying pathology in living patients. Therapeutic perspectives have emerged against tau aggregation, PGRN deficit and C9orf72 expansion. Presymptomatic carriers of genetic FTD would benefit, before onset of symptoms, from these therapeutics that would delay or prevent the disease. At this step, it becomes crucial to develop markers to know how many years before symptoms, the pathological process begins, to treat the patients at the earliest stage of the disease. Markers are also needed to predict the pathology (FTD-TDP/FTD-tau) in patients that will be eligible for trials targeting specific pathological lesion. The main objectives of the project are to identify novel cognitive, brain imaging markers and peripheral biomarkers for early diagnosis of FTLD, and to follow disease progression. Ninety participants including 8 patients and 82 'at-risk' individuals will be recruited and evaluated by clinical partners of the project (Paris, Lille, Rouen, Toulouse, Saint-Etienne, Marseille, Nantes). 'At-risk individuals' are the first- degree relatives of PGRN patients, who have a high a risk (50%) to carry the mutation.
Brain structural changes will be evaluated by voxel-based morphometry (SPM12 software) to assess global brain atrophy in one with the evaluation of atypical shape patterns such as cortical thickness (Freesurfer software) and the study of the cortical sulci (BrainVISA/Morphologist software).
Fluoro Deoxy DGlucose-Positron Emission Tomography (FDG-PET) will allow the identification of brain metabolic markers. Then voxel-based methods using Statistical Parametric Mapping software will be applied to compare different groups or analyze correlations between brain metabolism and cognitive deficits.
The identification of peripheral biomarkers of disease onset and disease progression will take advantage from RNA sequencing, in order to study gene expression and RNA splicing alterations in lymphocytes of patients and 'at risk individuals'.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for symptomatic patients:
Inclusion criteria
for 'at-risk' asymptomatic relatives:
Exclusion criteria
Exclusion criteria
for symptomatic patients:
Exclusion criteria
for 'at-risk' asymptomatic relatives :
Behavioral scales and neuropsychological tests; MRI, SPECT/PET
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Executive functions changes over time (rate of change in neuropsychological test)
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Cognitive flexibility changes over time (rate of change in neuropsychological test)
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Emotional assessment changes over time (rate of change in neuropsychological test)
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Social cognition changes over time (rate of change in neuropsychological test)
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Short-term memory changes over time (rate of change in neuropsychological test)
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Long-term memory changes over time (rate of change in neuropsychological test)
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Language changes over time (rate of change in neuropsychological test)
Time frame: at baseline 0 Months,at 42 Months, at 72 Months
Gestural praxis changes over time (rate of change in neuropsychological test)
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Behavioral changes over time (rate of change in neuropsychological questionnaire)
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Apathy changes over time (rate of change in neuropsychological questionnaire)
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Voxel-based methods using Statistical Parametric Mapping software will be applied to compare different groups or analyze correlations between brain atrophy/metabolism and cognitive deficits.
Time frame: at baseline 0 Months,at 42 Months,at 72 Months
Study gene expression and RNA splicing alterations in lymphocytes (RNA sequencing)
Assistance Publique - Hôpitaux de Paris
Other
Acronym: Predict-PGRN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01925196
Amyotrophic Lateral Sclerosis, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT04937452
Aphasia, Aphasia, Primary Progressive
Rome, <None>, Italy
View Trial DetailsNCT00604591
Brain Diseases, Central Nervous System Diseases
New York, United States
View Trial DetailsNCT04977245
Behavior, Behavioral Symptoms
San Francisco, California, United States
View Trial Details